Alnylam Pharmaceuticals
ALNY
#1130
Rank
C$28.35 B
Marketcap
C$211.74
Share price
-1.06%
Change (1 day)
-67.28%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

ESG Reports

Thumbnail Alnylam Pharmaceuticals
 ESG Report 2025

ESG Report 2025

Language: English

View ESG Report
Thumbnail Alnylam Pharmaceuticals
 ESG Report 2024

ESG Report 2024

Language: English

View ESG Report